Literature DB >> 475364

In vitro activity of furazlocillin (Bay k 4999) compared with those of mezlocillin, piperacillin, and standard beta-lactam antibiotics.

T D Gootz, C C Sanders, W E Sanders.   

Abstract

The activity of furazlocillin (Bay k 4999) was compared with those of mezlocillin, piperacillin, and standard beta-lactam antibiotics against a number of gram-positive and gram-negative organisms. These new expanded-spectrum penicillins were less active than penicillin G against most gram-positive organisms. Furazlocillin, mezlocillin, and piperacillin showed activity comparable to ampicillin and penicillin G against Haemophilus influenzae and penicillin-susceptible neisseriae, respectively. None of the drugs tested was effective against penicillin-resistant gonococci. The activity of furazlocillin was greater than that of mezlocillin, piperacillin, ampicillin, or carbenicillin against many Enterobacteriaceae. However, certain beta-lactam-resistant strains among these organisms were not highly susceptible to any of the three new penicillins. Furazlocillin was less active than piperacillin against Pseudomonas aeruginosa but was more active than carbenicillin or mezlocillin. Inoculum effects and discrepancies between minimal inhibitory concentrations and minimal bactericidal concentrations were observed with furazlocillin, mezlocillin, and piperacillin against several genera. The kinetics of bacterial killing by the new penicillins were often slow and incomplete over 24 h, especially in tests with Enterobacter and P. aeruginosa. Synergy was demonstrated between furazlocillin and aminoglycosides against a variety of gram-negative bacilli and Streptococcus faecalis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 475364      PMCID: PMC352759          DOI: 10.1128/AAC.15.6.783

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Beta-lactamase assays.

Authors:  G W Ross; C H O'Callaghan
Journal:  Methods Enzymol       Date:  1975       Impact factor: 1.600

2.  Piperacillin: in vitro evaluation.

Authors:  G P Bodey; B Le Blanc
Journal:  Antimicrob Agents Chemother       Date:  1978-07       Impact factor: 5.191

3.  Inhibition of cell division of Escherichia coli by a new synthetic penicillin, piperacillin.

Authors:  K Iida; S Hirata; S Nakamuta; M Koike
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

4.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

5.  Comparison of the in vitro activity of Bay k 4999 and piperacillin, two new antipseudomonal broad-spectrum penicillins, with other beta-lactam drugs.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

6.  Piperacillin, a new penicillin active against many bacteria resistant to other penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

7.  In vitro activity of piperacillin, a new semisynthetic penicillin with an unusually broad spectrum of activity.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

8.  Azlocillin and mezlocillin: new ureido penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

9.  In vitro studies of piperacilin, a new semisynthetic penicillin.

Authors:  D J Winston; D Wang; L S Young; W J Martin; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

10.  NEISSERIA GONORRHOEAE. I. VIRULENCE GENETICALLY LINKED TO CLONAL VARIATION.

Authors:  D S KELLOGG; W L PEACOCK; W E DEACON; L BROWN; D I PIRKLE
Journal:  J Bacteriol       Date:  1963-06       Impact factor: 3.490

  10 in total
  16 in total

Review 1.  Discovery and development of new antimicrobial agents.

Authors:  T D Gootz
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

2.  Attempted reduction of Abbott MS-2 false-susceptible errors for cefotaxime-resistant Pseudomonas aeruginosa by medium modification.

Authors:  D W Lander; D L Jungkind; L L Stone
Journal:  J Clin Microbiol       Date:  1987-04       Impact factor: 5.948

Review 3.  In vitro antibacterial effects of cephalosporins.

Authors:  J D Williams; F Moosdeen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  In vitro antimicrobial susceptibility of penicillinase-producing and intrinsically resistant Neisseria gonorrhoeae strains.

Authors:  M S Cohen; M H Cooney; E Blackman; P F Sparling
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

5.  In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agents.

Authors:  T Gootz; J Retsema; A Girard; E Hamanaka; M Anderson; S Sokolowski
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  Comparative in vitro antibacterial activity of seven semi-synthetic penicillins against aerobic gram-negative bacteria and enterococci.

Authors:  A Thabaut; J L Durosoir; P Saliou
Journal:  Infection       Date:  1982       Impact factor: 3.553

7.  Piperacillin plus vancomycin in the therapy of febrile episodes in cancer patients.

Authors:  L Jadeja; R Bolivar; V Fainstein; M Keating; K McCredie; M Hay; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

8.  Comparison of in vitro activity of moxalactam (LY127935) with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticarcillin against 420 blood culture isolates.

Authors:  L G Reimer; S Mirrett; L B Reller
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

9.  [N-formimidoyl-thienamycin: in vitro activity in bacteria with resistance to beta-lactam antibiotics or gentamicin].

Authors:  K Bartmann; R Tarbuc
Journal:  Infection       Date:  1982 Nov-Dec       Impact factor: 3.553

10.  False-susceptible results from the MS-2 system used for testing resistant Pseudomonas aeruginosa against two third-generation cephalosporins, moxalactam and cefotaxime.

Authors:  L L Stone; D L Jungkind
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.